{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:23:00Z","timestamp":1792635780611,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.neuropharm.2024.110063","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:39:06Z","timestamp":1720233546000},"page":"110063","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1\/Parkin pathway"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4585-2097","authenticated-orcid":false,"given":"Ao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangshang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6969-3228","authenticated-orcid":false,"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110063_bib1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbi.2020.09.017","article-title":"Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease","volume":"91","author":"Ahmed","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2024.110063_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081876","article-title":"Mitophagy regulates neurodegenerative diseases","volume":"10","author":"Cen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib3","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/jnr.23612","article-title":"Temporal kinetics of macrophage polarization in the injured rat spinal cord","volume":"93","author":"Chen","year":"2015","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2024.110063_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12974-020-01937-8","article-title":"CRID3, a blocker of apoptosis associated speck like protein containing a card, ameliorates murine spinal cord injury by improving local immune microenvironment","volume":"17","author":"Chen","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2024.110063_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029539","article-title":"The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes","volume":"6","author":"Coll","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.110063_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2024.110063_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","article-title":"Parkinson's disease: autoimmunity and neuroinflammation","volume":"15","author":"De Virgilio","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.neuropharm.2024.110063_bib10","article-title":"The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases","volume":"138","author":"Feng","year":"2021","journal-title":"Biomed. & Pharmacother. = Biomedecine & pharmacotherapie"},{"key":"10.1016\/j.neuropharm.2024.110063_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-018-0224-x","article-title":"Mechanism of parkin activation by PINK1","volume":"559","author":"Gladkova","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110063_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2024.110063_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/mds.115","article-title":"An update on adaptive deep brain stimulation in Parkinson's disease","volume":"33","author":"Habets","year":"2018","journal-title":"Mov. Disord. : Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.neuropharm.2024.110063_bib15","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1080\/15548627.2019.1596481","article-title":"Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease","volume":"15","author":"Han","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2024.110063_bib16","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1523\/JNEUROSCI.2324-19.2020","article-title":"Neuronal mitochondria modulation of LPS-induced neuroinflammation","volume":"40","author":"Harland","year":"2020","journal-title":"J. Neurosci. : Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110063_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells11010030","article-title":"Mitophagy: molecular mechanisms, new concepts on parkin activation and the emerging role of AMPK\/ULK1 Axis","volume":"11","author":"Iorio","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib18","article-title":"Cannabinoid receptor-2 attenuates neuroinflammation by promoting autophagy-mediated degradation of the NLRP3 inflammasome post spinal cord injury","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fmolb.2020.00037","article-title":"MCC950, a selective inhibitor of NLRP3 inflammasome, reduces the inflammatory response and improves neurological outcomes in mice model of spinal cord injury","volume":"7","author":"Jiao","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.neuropharm.2024.110063_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.neuropharm.2024.110063_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101816","article-title":"Proteostasis in Parkinson's disease: recent development and possible implication in diagnosis and therapeutics","volume":"84","author":"Kulkarni","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2024.110063_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104469","article-title":"Microglial mitophagy mitigates neuroinflammation in Alzheimer's disease","volume":"129","author":"Lautrup","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2024.110063_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord. : Off. J. Movement Disorder Soc."},{"key":"10.1016\/j.neuropharm.2024.110063_bib24","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00221-020-05916-6","article-title":"Protection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice","volume":"238","author":"Li","year":"2020","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110063_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175091","article-title":"Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome","volume":"928","author":"Li","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12974-023-02791-0","article-title":"The involvement of NLRP3 inflammasome in CUMS-induced AD-like pathological changes and related cognitive decline in mice","volume":"20","author":"Li","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2024.110063_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-981-16-2830-6_12","article-title":"Biomarkers of autophagy","volume":"1208","author":"Lin","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020283","article-title":"Interaction between parkin and \u03b1-synuclein in PARK2-mediated Parkinson's disease","volume":"10","author":"Madsen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020370","article-title":"Endogenous mechanisms of neuroprotection: to boost or not to boost","volume":"10","author":"Marmolejo-Mart\u00ednez-Artesero","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00019052-200108000-00008","article-title":"Parkin and Parkinson's disease","volume":"14","author":"Mizuno","year":"2001","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.neuropharm.2024.110063_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tcb.2016.05.008","article-title":"Deciphering the molecular signals of PINK1\/parkin mitophagy","volume":"26","author":"Nguyen","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071687","article-title":"Inflammation in Parkinson's disease: mechanisms and therapeutic implications","volume":"9","author":"Pajares","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib34","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.neuron.2022.05.009","article-title":"Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease","volume":"110","author":"Panicker","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110063_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2024.110063_bib36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bbi.2020.10.010","article-title":"Impaired autophagy in microglia aggravates dopaminergic neurodegeneration by regulating NLRP3 inflammasome activation in experimental models of Parkinson's disease","volume":"91","author":"Qin","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2024.110063_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40478-020-01062-w","article-title":"PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation","volume":"8","author":"Quinn","year":"2020","journal-title":"Acta Neuropathologica Commun."},{"key":"10.1016\/j.neuropharm.2024.110063_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101915","article-title":"Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson's disease","volume":"87","author":"Rajan","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2024.110063_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121885","article-title":"Innate immune cell death in neuroinflammation and Alzheimer's disease","volume":"11","author":"Rajesh","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbrc.2022.04.076","article-title":"MCC950 ameliorates the dementia symptom at the early age of line M83 mouse and reduces hippocampal \u03b1-synuclein accumulation","volume":"611","author":"Ren","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2024.110063_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115496","article-title":"GSK-3\u03b2: an exuberating neuroinflammatory mediator in Parkinson's disease","volume":"210","author":"Samim Khan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.148954","article-title":"Neuroprotective role of carvacrol via Nrf2\/HO-1\/NLRP3 axis in rotenone-induced PD mice model","volume":"1836","author":"Shah","year":"2024","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110063_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fphar.2015.00262","article-title":"NLRP3 inflammasome and its inhibitors: a review","volume":"6","author":"Shao","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41586-018-0448-9","article-title":"Parkin and PINK1 mitigate STING-induced inflammation","volume":"561","author":"Sliter","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110063_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2024.110063_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","article-title":"Regulation and function of NF-kappaB transcription factors in the immune system","volume":"27","author":"Vallabhapurapu","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","article-title":"The Lewy body in Parkinson's disease and related neurodegenerative disorders","volume":"47","author":"Wakabayashi","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","article-title":"Inflammation as a causative factor in the aetiology of Parkinson's disease","volume":"150","author":"Whitton","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.591475","article-title":"Exogenous alpha-synuclein evoked parkin downregulation promotes mitochondrial dysfunction in neuronal cells. Implications for Parkinson's disease pathology","volume":"13","author":"Wilkaniec","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110063_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010070","article-title":"Autophagy and macrophage functions: inflammatory response and phagocytosis","volume":"9","author":"Wu","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2024.110063_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101202","article-title":"Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases","volume":"65","author":"Wu","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2024.110063_bib53","article-title":"NLRP3 deficiency protects against intermittent hypoxia-induced neuroinflammation and mitochondrial ROS by promoting the PINK1-parkin pathway of mitophagy in a murine model of sleep apnea","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13834","article-title":"Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease","volume":"22","author":"Yan","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.neuropharm.2024.110063_bib55","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3389\/fimmu.2019.02538","article-title":"Pharmacological inhibitors of the NLRP3 inflammasome","volume":"10","author":"Zahid","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib56","first-page":"248","article-title":"Parkin regulation and neurodegenerative disorders","volume":"7","author":"Zhang","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110063_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-021-02334-5","article-title":"Mitophagy in neurological disorders","volume":"18","author":"Zhang","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2024.110063_bib58","article-title":"LPS activates neuroinflammatory pathways to induce depression in Parkinson's disease-like condition","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2024.110063_bib59","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41598-019-42286-8","article-title":"Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice","volume":"9","author":"Zhao","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:13:39Z","timestamp":1723587219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824002326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":59,"alternative-id":["S0028390824002326"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110063","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of NLRP3 inflammasome ameliorates LPS-induced neuroinflammatory injury in mice via PINK1\/Parkin pathway","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110063"}}